The role of dual antithrombotic strategy (low-dose rivaroxaban + aspirin) in therapy: Joint consensus document of the Hungarian Society of Angiology and Vascular Surgery (MAÉT), the Hungarian Society of Cardiology (MKT) and the Hungarian Stroke Society (MST)
Every second person in Hungary dies because of cardiovascular disease. Cardiovascular (CV) disease and mortality are more common in patients who have already had a CV event. Thus, secondary prevention treatment is of paramount importance in improving morbidity and mortality indicators in Hungary. On...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Promenade Kft
2025-02-01
|
| Series: | Cardiologia Hungarica |
| Subjects: | |
| Online Access: | https://cardiologia.hungarica.eu/archive/2025-issues/volume-55-issue-1/the-role-of-dual-antithrombotic-strategy-low-dose-rivaroxaban-aspirin-in-therapy-joint-consensus-document-of-the-hungarian-society-of-angiology-and-vascular-surgery-mat-the-hungarian-society-of-cardiology-mkt-and-the-hungarian-stroke-society-mst |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Every second person in Hungary dies because of cardiovascular disease. Cardiovascular (CV) disease and mortality are more common in patients who have already had a CV event. Thus, secondary prevention treatment is of paramount importance in improving morbidity and mortality indicators in Hungary. One of the essential elements of secondary CV prevention is antithrombotic therapy. In addition to conventional antiplatelet treatment, dual antithrombotic treatment (low dose rivaroxaban + aspirin) has emerged as a therapeutic option in the past decade based on the results of large, international, randomized studies. Among the Hungarian scientific societies dealing with atherosclerotic vascular diseases, the experts of the Hungarian Society of Angiology and Vascular Surgery, the Hungarian Society of Cardiology and the Hungarian Society of Stroke wished to summarize in this consensus document the place and significance of double antithrombotic treatment for specialists treating atherosclerotic vascular patients. |
|---|---|
| ISSN: | 0133-5596 1588-0230 |